


AMENDMENTS TO THE CLAIMS**In the Claims:**

The following listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A glucagon-like peptide-1 receptor agonist having the following structural formula:




wherein, each of Ar₁ and Ar₂ independently is ~~phenyl or~~ substituted phenyl, and the substituent groups of the said substituted phenyl is are one, two or three groups optionally selected from the following group groups: alkyl; hydroxyl; substituted alkoxyl or alkylamino which contains the substituent groups including halogen, alkoxyl or hydroxyl; substituted alkanoylxy or alkanoylamino which contains the substituent groups including halogen, alkoxyl or hydroxyl; C₂-C₆ alkenyl substituted with oxygen or amine, phenyl, benzyl, C₂-C₆ enoyl, C₃-C₆ cycloalkanoyl, benzoyl, substituted benzoyl which contains optional one, two or three substituent groups including alkoxyl and alkanoylamino, benzoyl, thenoyl, tert-butoxycarbonyl, adamantane formoxyl, and mandeloyl; alkoxyl; alkylamino; cycloalkoxyl; cycloalkylamino; amino; amide; alkoxycarbonyl; cycloalkoxycarbonyl; alkanoylxy; alkanoylamino; cycloalkanoylxy; cycloalkanoylamino; carbamido; urylene; alkanoyl; nitro; carboxyl; and aldehyde group;

X is O, ~~S,~~ or NH; and


Y is O ~~or~~ S.

2. (Currently amended) The glucagon-like peptide-1 receptor agonist according to the claim 1, being characterized in that wherein:




wherein R₁ is any one of the following substituent groups: H; alkyl; substituted alkyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C₂-C₆ alkenyl; C₃-

~~C₆-cycloalkyl; phenyl; benzyl~~; alkanoyl; substituted alkanoyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C₂-C₆ enoyl; C₃-C₆ cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxyl and alkylamino; tert-butoxycarbonyl; ~~benzoyl~~; thenoyl; adamantane formoxyl; and mandeloyl; and X₁ is O or NH,




wherein R₂ is any one of the following substituent groups: ~~H; alkyl; substituted alkyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C₂-C₆ alkenyl; C₃-C₆ cycloalkyl; phenyl; benzyl~~; alkanoyl; substituted alkanoyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C₂-C₆ enoyl; C₃-C₆ cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxyl and alkylamino; tert-butoxycarbonyl; ~~benzoyl~~; thenoyl; adamantane formoxyl; and mandeloyl; and X₂ is O or NH;




wherein each of R₃ and R₄ independently is any one of the following substituent groups: ~~H; alkyl; substituted alkyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C₂-C₆ alkenyl; C₃-C₆ cycloalkyl; phenyl; benzyl~~; alkanoyl; substituted alkanoyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C₂-C₆ enoyl; C₃-C₆ cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxyl and alkylamino; tert-butoxycarbonyl; ~~benzoyl~~; thenoyl; adamantane formoxyl; and mandeloyl; and X₁ is O or NH; X₂ is O or NH.


3. (Currently amended) The glucagon-like peptide-1 receptor agonist according to the claim 1, ~~being characterized in that,~~ wherein:



wherein each of R₅ and R₆ independently is any one of the following substituent groups: ~~H~~; alkyl; substituted alkyl which contains the substituent groups including halogen, alkoxy or hydroxyl; C₂-C₆ alkenyl; C₃-C₆ cycloalkyl; ~~phenyl; benzyl;~~ alkanoyl; substituted alkanoyl which contains the substituent groups including halogen, alkoxy or hydroxyl; C₂-C₆ enoyl; C₃-C₆ cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxy and alkylamino; tert-butoxycarbonyl; ~~benzoyl;~~ thenoyl; adamantane formoxyl; and mandeloyl; and X₁ is O or NH; X₂ is O or NH,



wherein R₂ is any one of the following substituent groups: ~~H~~; alkyl; substituted alkyl which contains substituent groups including halogen, alkoxy or hydroxyl; C₂-C₆ alkenyl; C₃-C₆ cycloalkyl; ~~phenyl; benzyl;~~ alkanoyl; substituted alkanoyl which contains substituent groups including halogen, alkoxy or hydroxyl; C₂-C₆ enoyl; C₃-C₆ cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxy and alkylamino; tert-butoxycarbonyl; ~~benzoyl;~~ thenoyl; adamantane formoxyl; and mandeloyl; and X₂ is O or NH;




wherein each of R₃ and R₄ independently is any one of the following substituent groups: ~~H~~; alkyl; substituted alkyl which contains substituent groups including halogen, alkoxy or hydroxyl; C₂-C₆ alkenyl; C₃-C₆ cycloalkyl; ~~phenyl; benzyl;~~ alkanoyl; substituted alkanoyl which contains the substituent groups including halogen, alkoxy or hydroxyl; C₂-C₆ enoyl; C₃-C₆ cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxy and alkylamino; tert-butoxycarbonyl; ~~benzoyl;~~ thenoyl; adamantane formoxyl; and mandeloyl; and X₁ is O or NH; X₂ is O or NH.

4-8. (Canceled).

9. (Original) Use of the glucagon-like peptide-1 receptor agonist according to claim 1 as medicaments for treating the carbohydrate metabolism disturbance-related diseases such as type II diabetes, insensitivity to insulin or obesity, etc.

10. (New) The glucagon-like peptide-1 receptor agonist according to the claim 1 having the following structural formula:



wherein R_1 is any one of the following substituent groups: alkanoyl; substituted alkanoyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C_2 - C_6 enoyl; C_3 - C_6 cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxyl and alkylamino; tert-butoxycarbonyl; thenoyl; adamantane formoyl; and mandeloyl;

each of R_2 and R_3 independently is any one of the following substituent groups: alkyl; substituted alkyl which contains substituent groups including halogen, alkoxyl or hydroxyl; C_3 - C_6 cycloalkyl; alkanoyl; substituted alkanoyl which contains the substituent groups including halogen, alkoxyl or hydroxyl; C_2 - C_6 enoyl; C_3 - C_6 cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxyl and alkylamino; tert-butoxycarbonyl; thenoyl; adamantane formoyl; and mandeloyl;

X is O;

Y is O;

X_1 is O;

X_2 is NH;

X_3 is O.

11. (New) The glucagon-like peptide-1 receptor agonist according to the claim 1 having the following structural formula:

